| Literature DB >> 17293228 |
Janice K Ryu1, Suzanne Swann, Francis LeVeque, Charles W Scarantino, Darlene Johnson, Allan Chen, Andre Fortin, JonDavid Pollock, Harold Kim, Kian K Ang.
Abstract
PURPOSE: Based on early clinical evidence of potential mucosal protection by granulocyte-macrophage colony stimulating factor (GM-CSF), the Radiation Therapy Oncology Group conducted a double-blind, placebo-controlled, randomized study to test the efficacy and safety of GM-CSF in reducing the severity and duration of mucosal injury and pain (mucositis) associated with curative radiotherapy (RT) in head-and-neck cancer patients. METHODS AND MATERIALS: Eligible patients included those with head-and-neck cancer with radiation ports encompassing >50% of oral cavity and/or oropharynx. Standard RT ports were used to cover the primary tumor and regional lymphatics at risk in standard fractionation to 60-70 Gy. Concurrent cisplatin chemotherapy was allowed. Patients were randomized to receive subcutaneous injection of GM-CSF 250 microg/m2 or placebo 3 times a week. Mucosal reaction was assessed during the course of RT using the National Cancer Institute Common Toxicity Criteria and the protocol-specific scoring system.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17293228 DOI: 10.1016/j.ijrobp.2006.09.043
Source DB: PubMed Journal: Int J Radiat Oncol Biol Phys ISSN: 0360-3016 Impact factor: 7.038